John E Kraus
Overview
Explore the profile of John E Kraus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbins K, Bissonnette R, Maeda-Chubachi T, Ye L, Peppers J, Gallagher K, et al.
J Am Acad Dermatol
. 2019 Jan;
80(3):714-721.
PMID: 30612986
Background: There is a significant need for novel, safe, and efficacious topical treatments for psoriasis. Objective: We assessed the safety and efficacy of tapinarof in a new cream formulation at...
2.
Peppers J, Paller A, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, et al.
J Am Acad Dermatol
. 2018 Dec;
80(1):89-98.e3.
PMID: 30554600
Background: Safe and efficacious topical treatments are needed for atopic dermatitis (AD). Objective: We assessed the safety and efficacy of tapinarof cream (2 concentrations and 2 application frequencies) in patients...
3.
Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald C, et al.
Neuromuscul Disord
. 2017 Dec;
28(1):4-15.
PMID: 29203355
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated efficacy and safety of subcutaneous drisapersen 6 mg/kg/week in 186 ambulant boys aged ≥5 years, with Duchenne muscular dystrophy (DMD)...
4.
Findling R, Chang K, Robb A, Foster V, Horrigan J, Krishen A, et al.
J Am Acad Child Adolesc Psychiatry
. 2015 Nov;
54(12):1020-1031.e3.
PMID: 26598477
Objective: This study aimed to compare the efficacy of lamotrigine versus placebo in 10- to 17-year-olds with bipolar I disorder (BP-I) who were receiving conventional bipolar disorder treatment. Method: In...
5.
Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al.
Lancet Neurol
. 2014 Sep;
13(10):987-96.
PMID: 25209738
Background: Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle deterioration and preferentially affects boys. Antisense-oligonucleotide-induced exon skipping allows synthesis of partially functional dystrophin. We investigated the efficacy and...
6.
Flanigan K, Voit T, Rosales X, Servais L, Kraus J, Wardell C, et al.
Neuromuscul Disord
. 2013 Dec;
24(1):16-24.
PMID: 24321374
Duchenne muscular dystrophy (DMD) is a progressive, lethal neuromuscular disorder caused by the absence of dystrophin protein due to mutations of the dystrophin gene. Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed...
7.
Carpenter D, Fong R, Kraus J, Davies J, Moore C, Thase M
J Clin Psychiatry
. 2011 Mar;
72(11):1503-14.
PMID: 21367354
Objective: This meta-analysis of placebo-controlled paroxetine trials examines suicidality incidence in adults, focusing on disorder and age as potential risk factors. The findings are put in context with an efficacy...
8.
Grotjahn D, Kraus J, Amouri H, Rager M, Cooksy A, Arita A, et al.
J Am Chem Soc
. 2010 May;
132(23):7919-34.
PMID: 20486707
Hydrogen bonding phenomena are explored using a combination of X-ray diffraction, NMR and IR spectroscopy, and DFT calculations. Three imidazolylphosphines R(2)PImH (ImH = imidazol-2-yl, R = t-butyl, i-propyl, phenyl, 1a-1c)...
9.
Kraus J, Horrigan J, Carpenter D, Fong R, Barrett P, Davies J
J Affect Disord
. 2009 May;
120(1-3):40-7.
PMID: 19439363
Background: Understanding suicidal behavior is an important component of assessing suicidality in psychiatric patients. GlaxoSmithKline (GSK) conducted a meta-analysis of randomized, placebo-controlled trials to compare suicidality in adult patients treated...
10.
Sheehan D, Keene M, Eaddy M, Krulewicz S, Kraus J, Carpenter D
CNS Drugs
. 2008 Oct;
22(11):963-73.
PMID: 18840035
Background: Given the number of antidepressants available and their rising costs, healthcare payers have initiated restrictive reimbursement policies for newer antidepressants, without consideration for differences in their effectiveness or tolerability....